Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, reimbursement complexities, and insufficient economic incentives slow the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...

The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...